-
-
-
-
-
-
-
Entasis Therapeutics and Zai Lab Complete Patient Enrollment in the ATTACK Phase 3 Registrational Clinical Trial of Sulbactam-Durlobactam
-
-
-
-
-
-
-
Antengene Corporation Closes US$97 Million Series C Financing to Support Ongoing Drug Development and Preparations for Potential Commercialization
-
-
-
-
-
-
-
Five Prime Therapeutics Reports Fourth Quarter and Full Year 2019 Results
-
-
-
-
-
-
-
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
-
-
-
-
-
923,755 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All